Science applied to regenerative medicine
— with ethics, evidence and governance.
CellPraxis integrates cell-based platforms and bioactives derived from umbilical cord to develop advanced therapies and translational research programs.
Informational content. Does not replace professional medical consultation.
Integrated research platforms
We combine cutting-edge science with regulatory rigor to develop solutions in regenerative medicine.
Terapias Celulares e Produtos Biológicos
Desenvolvimento de PTAs/ATMPs com foco em células mesenquimais (MSCs), CD34+ e derivados de cordão umbilical.
Exossomos/EVs e miRNAs
Pesquisa e formulações baseadas em vesículas extracelulares e microRNAs para aplicações tópicas e sistêmicas.
Programas Clínicos e Translacionais
Desenho de estudos com endpoints clínicos relevantes, do pré-clínico à validação em humanos.
Qualidade, Rastreabilidade e Compliance
Padrões CMC/GMP, farmacovigilância e governança em todas as etapas do desenvolvimento.
Nota: Os programas apresentados estão em diferentes estágios de desenvolvimento. Resultados mencionados referem-se a estudos científicos e não constituem garantia de eficácia clínica.
Programs and platforms in development
Each program represents a research line with specific objectives, always guided by evidence and governance.
Why now?
The advanced therapies sector is undergoing transformation. Regulatory approvals of CAR-T, gene therapies and cell products demonstrate that science can reach patients — but also teach that rigor, transparency and pharmacovigilance are non-negotiable.
Accelerated Global Growth
The cell and gene therapy market is growing exponentially, with new regulatory approvals each year.
Approved CAR-T and Gene Therapies
Kymriah, Yescarta, Zynteglo and others demonstrate that advanced therapies can reach the market with robust evidence.
Pharmacovigilance Lessons
Market withdrawals (like Alofisel in Europe) reinforce: continuous evidence and robust data are essential.
Window of Opportunity
Brazil can position itself strategically in ATMP development with local capacity and global standards.
2024 Market Value
"Innovation is fast, but medicine is rigorous: evidence and safety guide the way."
Estimates vary by methodology. Sources: Nova One Advisor, Fortune Business Insights, Grand View Research, ARM.
Leadership committed to ethics and excellence
Our team combines scientific expertise, regulatory experience and commitment to governance in advanced therapies.
Luis Eduardo Da Cruz
Research & Development (R&D) Manager
Coordinates R&D strategy, study design, CMC/quality and integration between science and product.
Simone Amaral da Silva Cruz
Corporate Efficiency Manager
Leads operational excellence and corporate efficiency — essential for sustainability and scale in biotechnology.
Dr. Carolina Cruz
Medical Director
Medical supervision of clinical programs, protocol design and interface with investigators.
"Translating research into product requires balancing innovation, safety, clinical evidence and the patient's real context. The challenge is to advance with scientific rigor, relevant endpoints and transparency — so that regenerative medicine generates concrete health benefits."
Preclinical
In vitro and animal model studies to assess safety and mechanism of action.
Phase I
First human tests focused on safety and tolerability.
Phase II
Preliminary efficacy evaluation in specific population with clinical endpoints.
Phase III
Large-scale randomized controlled studies to confirm efficacy.
Real World
Pharmacovigilance and post-registration evidence in diverse population.
How we talk about evidence
The journey of an advanced therapy — from laboratory to patient — goes through multiple validation stages. Each phase answers different questions about safety, efficacy and applicability.
At CellPraxis, we are transparent about what stage each program is at. This means not promising results before obtaining them — and communicating both advances and challenges.
What we evaluate:
- Level of evidence (RCT, observational studies, case reports)
- Relevant and validated clinical endpoints
- Safety profile and adverse events
- Regulatory status and compliance
Common questions about regenerative medicine
Direct, evidence-based answers to the most frequent questions.
This content is informational and educational. It does not replace consultation with a qualified healthcare professional. For specific questions, consult your doctor.
Ready to explore the future of regenerative medicine?
Connect with our team to discuss science, partnerships or simply learn more about our research platforms.